[HTML][HTML] S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis

…, B Hellmich, JU Holle, C Kneitz, I Kötter… - Zeitschrift für …, 2017 - Springer
Erstellt unter Federführung der Deutschen GesellschaftfürRheumatologie (DGRh) assoziierten
Vaskulitiden (AAV). Zu den ANCA-assoziierten Vaskulitiden zählen die Granulomatose …

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

…, A Kotulska, C Denton, PC Coelho, I Kötter… - Annals of the …, 2010 - ard.bmj.com
Objectives To determine the causes and predictors of mortality in systemic sclerosis (SSc).
Methods Patients with SSc (n=5860) fulfilling the American College of Rheumatology criteria …

2018 update of the EULAR recommendations for the management of Behçet's syndrome

…, AF Celik, F Fortune, J Gaudric, A Gul, I Kötter… - Annals of the …, 2018 - ard.bmj.com
Several new treatment modalities with different mechanisms of action have been studied in
patients with Behçet’s syndrome (BS). The aim of the current effort was to update the …

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

…, AA Van De Loosdrecht, T Daikeler, I Kötter… - Jama, 2014 - jamanetwork.com
Importance High-dose immunosuppressive therapy and autologous hematopoietic stem cell
transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small …

Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe

CC Zouboulis, I Kotter, D Djawari, W Kirch… - Yonsei medical …, 1997 - eymj.org
The German Registry of Adamantiades-BehÇet's disease was founded in 1990 in Berlin and
it provides current data on the epidemiology, the clinical manifestations and the course of …

[HTML][HTML] DGRh-S2e-Leitlinie

…, J Rech, M Fleck, N Blank, JP Haas, I Kötter… - Zeitschrift für …, 2022 - Springer
5. Methodik Die methodischen Grundlagen der Leitlinienerstellung inklusive
Empfehlungserarbeitung mit Schlüsselfragen, Suchstrategien, Evidenz-und Biasbewertung sind im …

[HTML][HTML] Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for …

…, J Van Laar, J Ouyang, T Kozak, J Moore, I Kötter… - …, 2010 - ncbi.nlm.nih.gov
Background Autologous hematopoietic stem cell transplantation has been used since 1996
for the treatment of severe autoimmune diseases refractory to approved therapies. We …

Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis

I Kötter, M Zierhut, AK Eckstein, R Vonthein… - British Journal of …, 2003 - bjo.bmj.com
Background: Behçet's disease is a multisystem vasculitis of unknown origin. Standard
treatment mainly comprises systemic immunosuppressive agents. Ocular involvement, mostly …

The use of interferon α in Behçet disease: review of the literature

I Kötter, I Günaydin, M Zierhut, N Stübiger - Seminars in arthritis and …, 2004 - Elsevier
OBJECTIVES: To evaluate the efficacy and safety of interferon (IFN) alpha for the treatment
of Behçet’s disease (BD) and discuss its possible mechanisms of action. METHODS: Reports …

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

…, B Fautrel, J Rech, F Spertini, E Feist, I Kötter… - Annals of the …, 2018 - ard.bmj.com
Objectives Adult-onset Still’s disease (AOSD) is a rare systemic autoinflammatory disease;
its management is largely empirical. This is the first clinical study to determine if interleukin (IL)…